Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014 Oct;140(10):1783-93.
doi: 10.1007/s00432-014-1715-2. Epub 2014 Jun 6.

Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study

Cesare Gridelli  1 , Filippo de Marinis, Andrea Ardizzoni, Silvia Novello, Gabriella Fontanini, Federico Cappuzzo, Francesco Grossi, Antonio Santo, Diego Cortinovis, Adolfo Favaretto, Vito Lorusso, Domenico Galetta, Salvatore Siena, Anna Bettini, Monica Iurlaro, Alberto Caprioli; LIFE study team
Collaborators, Affiliations
Observational Study

Advanced non-small cell lung cancer management in patients progressing after first-line treatment: results of the cross-sectional phase of the Italian LIFE observational study

Cesare Gridelli et al. J Cancer Res Clin Oncol. 2014 Oct.

Abstract

Purpose: LIFE (non-small cell Lung cancer management In patients progressing after First-linE of treatment in the metastatic setting) is a multicentre Italian observational study, including a cross-sectional and a longitudinal phase, with the aim of describing the therapeutic approach in clinical practice for advanced non-small cell lung cancer (NSCLC) patients, progressing after first-line treatment.

Methods: In this paper, the cross-sectional phase is outlined, with the primary endpoint of describing the proportion of patients receiving second-line treatment among those progressed during or after first-line treatment according to clinical practice.

Results: From July 2011 to January 2012, 603 patients were enrolled and 541 (90 %) were evaluable. A total of 464 (86 %) patients received a second-line therapy outside clinical trials. Chemotherapy and targeted therapies were administered to 65 and 34 % of patients, respectively (1 % both). No tissue collection was required within the observational trial, and biomarkers analysis was performed at diagnosis or later in 314 patients (58 %). In details, activating epidermal growth factor receptor mutations were detected in 21 % of 311 evaluable patients, Kirsten rat sarcoma 2 viral oncogene homolog mutation in 22 % of the 77 evaluable patients and anaplastic lymphoma kinase translocations analysis was performed in 74 patients and resulted positive in 23 % of cases. These high proportions were probably due to enriched patient population tested.

Conclusions: These results showed a pattern of care for NSCLC second-line therapy which reflects international guidelines recommendations and current expected clinical practice. Interestingly, biomarkers analyses were performed in a higher percentage than expected.

PubMed Disclaimer

Conflict of interest statement

The authors declare to have full control of all primary data, and they agree to allow the journal to review their data if requested. Authors declare the following conflict of interest: Gridelli Cesare, Grossi Francesco had received advisory/speaker honoraria and/or research funding from Boehringer Ingelheim Italy. de Marinis Filippo has received advisory/speaker honoraria and/or research funding from Boehringer Ingelheim Italy and Roche. Ardizzoni Andrea has received advisory/speaker honoraria and/or research funding from Boehringer Ingelheim Italy, Glaxo Smith-Kline, Eli Lilly, Pfizer, Pierre Fabre, Daiicki-Sankyo. Novello Silvia, Cortinovis Diego had received advisory/speaker honoraria and/or research funding from Boehringer Ingelheim Italy, Roche, Astra Zeneca, Eli Lilly. The following authors declare no conflict of interest instead: Cappuzzo Federico, Favaretto Adolfo, Bettini Anna, Siena Salvatore, Caprioli Alberto, Iurlaro Monica, Fontanini Gabriella, Santo Antonio, Lorusso Vito, Galetta Domenico.

Figures

Fig. 1
Fig. 1
Study diagram. (The arrows from T = 0 to T = 6 months delimit the period of patients enrolment lasting 6 months—cross-sectional phase of the study. The dotted arrow indicates the 6 months prior to baseline, during which the included patients must have experienced progression of disease following a first-line treatment. The arrows from T = 6 months to T = 12 months delimit the patients observation period lasting 6 months—longitudinal phase of the study)
Fig. 2
Fig. 2
Patient’s symptoms at diagnosis. A bar graph displays the percentage of cancer-related symptoms at diagnosis
See this image and copyright information in PMC

References

    1. Azzoli CG, Temin S, Aliff T, Baker S Jr, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G (2011) 2011 focused update of 2009 American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 29:3825–3831 - PMC - PubMed
    1. Bischoff HG, van den Borne B, Pimentel FL, Arellano J, Langer F, Leschinger MI, Thatcher N (2010) Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study). Curr Med Res Opin 26:1461–1470 - PubMed
    1. de Marinis F, Rossi A, Di Maio M, Ricciardi S, Gridelli C (2011) Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer 73:1–10 - PubMed
    1. Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM, Gebbia V, Smit EF, Morabito A, Gallo C, Perrone F, Gridelli C (2009) Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 27:1836–1843 - PubMed
    1. Dixon WJ, Massey FJ (1983) Introduction to statistical analysis, 4th edn. McGraw-Hill, New York, pp 105–107

Publication types

MeSH terms

LinkOut - more resources